Vigabatrin-associated retinal damage - potential biochemical mechanisms

Acta Neurologica Scandinavica

Volumn 126, Issue 4, 2012, Pages 219-228

  Heim, M K ^a   Gidal, B E ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Gamma aminobutyric acid; Ornithine; Retinal diseases; Taurine; Vigabatrin; Vision disorders

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID C RECEPTOR; ORNITHINE; TAURINE; TIAGABINE; VIGABATRIN;

AMINO ACID DEFICIENCY; CYTOTOXICITY; ELECTRORETINOGRAM; EXCITOTOXICITY; FOCAL EPILEPSY; HUMAN; LIGHT EXPOSURE; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHOTOTOXICITY; RETINA CELL; RETINA DEGENERATION; RETINA INJURY; REVIEW; SEIZURE; VISUAL IMPAIRMENT;

ANIMALS; ANTICONVULSANTS; EPILEPSY; HUMANS; RETINAL DISEASES; TAURINE; VIGABATRIN;

EID: 84865788445     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2012.01684.x     Document Type: Review

References (85)

1. Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol 2003;16:165-170.
2. Sander JW. Some aspects of prognosis in the epilepsies: a review. Epilepsia 1993;34:1007-1016.
3. Sperling MR. The consequences of uncontrolled epilepsy. CNS Spectr 2004;9:98-101, 106-9.
4. Wheless JW. Intractable epilepsy: a survey of patients and caregivers. Epilepsy Behav 2006;8:756-764.
5. Grant SM, Heel RC. Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991;41:889-926.
6. Ben-Menachem E. Mechanism of action of vigabatrin: correcting misperceptions. Acta Neurol Scand 2011;124(Suppl 192):5-15.
7. Sabril full prescribing information. Deerfield, IL: Lundbeck, Inc., 2009.
8. Hemming K, Maguire MJ, Hutton JL, Marson AG. Vigabatrin for refractory partial epilepsy. Cochrane Database Syst Rev 2008;CD007302.
9. Appleton RE. The role of vigabatrin in the management of infantile epileptic syndromes. Neurology 1993;43(11 Suppl 5):S21-3.
10. Riikonen R. Long-term outcome of West syndrome: a study of adults with a history of infantile spasms. Epilepsia 1996;37:367-372.
11. Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane Database Syst Rev 2008;CD001770.
12. Carmant L. Vigabatrin therapy for infantile spasms: review of major trials in Europe, Canada, and the United States; and recommendations for dosing. Acta Neurol Scand 2011;124(Suppl 192):36-47.
13. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997;314:180-181.
14. Sergott RC, Bittman RM, Christen EM, Sagar SM. Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy. Epilepsy Res 2010;92:170-176.
15. Maguire MJ, Hemming K, Wild JM, Hutton JL, Marson AG. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. Epilepsia 2010;51:2423-2431.
16. Kinirons P, Cavalleri GL, Singh R, Shahwan A, Acheson JF, Wood NW et al. A pharmacogenetic exploration of vigabatrin-induced visual field constriction. Epilepsy Res 2006;70:144-152.
17. Willmore LJ, Abelson MB, Ben-Menachem E, Pellock JM, Shields WD. Vigabatrin: 2008 update. Epilepsia 2009;50:163-173.
18. Waterhouse EJ, Mims KN, Gowda SN. Treatment of refractory complex partial seizures: role of vigabatrin. Neuropsychiatr Dis Treat 2009;5:505-515.
19. Wheless JW, Carmant L, Bebin M, Conry JA, Chiron C, Elterman RD et al. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia 2009;50:195-205.
20. Cohen JA, Fisher RS, Brigell MG, Peyster RG, Sze G. The potential for vigabatrin-induced intramyelinic edema in humans. Epilepsia 2000;41:148-157.
21. Herrmann R, Heflin SJ, Hammond T, Lee B, Wang J, Gainetdinov RR et al. Rod vision is controlled by dopamine-dependent sensitization of rod bipolar cells by GABA. Neuron 2011;72:101-110.
22. Buncic JR, Westall CA, Panton CM, Munn JR, MacKeen LD, Logan WJ. Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children. Ophthalmology 2004;111:1935-1942.
23. Wild JM, Robson CR, Jones AL, Cunliffe IA, Smith PE. Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer. Invest Ophthalmol Vis Sci 2006;47:917-924.
24. Johnson MA, Krauss GL, Miller NR, Medura M, Paul SR. Visual function loss from vigabatrin: effect of stopping the drug. Neurology 2000;55:40-45.
25. Arndt CF, Derambure P, Defoort-Dhellemmes S, Hache JC. Outer retinal dysfunction in patients treated with vigabatrin. Neurology 1999;52:1201-1205.
26. Lawden MC, Eke T, Degg C, Harding GF, Wild JM. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 1999;67:716-722.
27. Clayton LM, Devile M, Punte T, Kallis C, de Haan GJ, Sander JW et al. Retinal nerve fiber layer thickness in vigabatrin-exposed patients. Ann Neurol 2011;69:845-854.
28. Moseng L, Saeter M, Morch-Johnsen GH, Hoff JM, Gajda A, Brodtkorb E et al. Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity. Acta Ophthalmol 2011;89:452-458.
29. Wang QP, Jammoul F, Duboc A, Gong J, Simonutti M, Dubus E et al. Treatment of epilepsy: the GABA-transaminase inhibitor, vigabatrin, induces neuronal plasticity in the mouse retina. Eur J Neurosci 2008;27:2177-2187.
30. Duboc A, Hanoteau N, Simonutti M, Rudolf G, Nehlig A, Sahel JA et al. Vigabatrin, the GABA-transaminase inhibitor, damages cone photoreceptors in rats. Ann Neurol 2004;55:695-705.
31. Gottlob I, Wundsch L, Pflug R. Possible role of amacrine cells in the generation of the mammalian ERG b-wave. Doc Ophthalmol 1985;61:55-63.
32. Shiells RA, Falk G. Contribution of rod, on-bipolar, and horizontal cell light responses to the ERG of dogfish retina. Vis Neurosci 1999;16:503-511.
33. Abbott CJ, McBrien NA, Grunert U, Pianta MJ. Relationship of the optical coherence tomography signal to underlying retinal histology in the tree shrew (Tupaia belangeri). Invest Ophthalmol Vis Sci 2009;50:414-423.
34. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998;50:614-618.
35. Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A, Zackon D. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 1999;106:1792-1798.
36. McDonagh J, Stephen LJ, Dolan FM, Parks S, Dutton GN, Kelly K et al. Peripheral retinal dysfunction in patients taking vigabatrin. Neurology 2003;61:1690-1694.
37. Lascaratos G, Ji D, Wood JP, Osborne NN. Visible light affects mitochondrial function and induces neuronal death in retinal cell cultures. Vision Res 2007;47:1191-1201.
38. Izumi Y, Ishikawa M, Benz AM, Izumi M, Zorumski CF, Thio LL. Acute vigabatrin retinotoxicity in albino rats depends on light but not GABA. Epilepsia 2004;45:1043-1048.
39. Jammoul F, Wang Q, Nabbout R, Coriat C, Duboc A, Simonutti M et al. Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity. Ann Neurol 2009;65:98-107.
40. Hosking SL, Hilton EJ. Neurotoxic effects of GABA-transaminase inhibitors in the treatment of epilepsy: ocular perfusion and visual performance. Ophthalmic Physiol Opt 2002;22:440-447.
41. Cubells JF, Blanchard JS, Smith DM, Makman MH. In vivo action of enzyme-activated irreversible inhibitors of glutamic acid decarboxylase and gamma-aminobutyric acid transaminase in retina vs. brain. J Pharmacol Exp Ther 1986;238:508-514.
42. Sills GJ, Patsalos PN, Butler E, Forrest G, Ratnaraj N, Brodie MJ. Visual field constriction: accumulation of vigabatrin but not tiagabine in the retina. Neurology 2001;57:196-200.
43. Sills GJ, Butler E, Forrest G, Ratnaraj N, Patsalos PN, Brodie MJ. Vigabatrin, but not gabapentin or topiramate, produces concentration-related effects on enzymes and intermediates of the GABA shunt in rat brain and retina. Epilepsia 2003;44:886-892.
44. Neal MJ, Cunningham JR, Shah MA, Yazulla S. Immunocytochemical evidence that vigabatrin in rats causes GABA accumulation in glial cells of the retina. Neurosci Lett 1989;98:29-32.
45. Staley KJ, Soldo BL, Proctor WR. Ionic mechanisms of neuronal excitation by inhibitory GABAA receptors. Science 1995;269:977-981.
46. Wang Y, Qin ZH. Molecular and cellular mechanisms of excitotoxic neuronal death. Apoptosis 2010;15:1382-1402.
47. Chen Q, Olney JW, Lukasiewicz PD, Almli T, Romano C. Ca2+-independent excitotoxic neurodegeneration in isolated retina, an intact neural net: a role for Cl- and inhibitory transmitters. Mol Pharmacol 1998;53:564-572.
48. Chen Q, Moulder K, Tenkova T, Hardy K, Olney JW, Romano C. Excitotoxic cell death dependent on inhibitory receptor activation. Exp Neurol 1999;160:215-225.
49. Varela C, Blanco R, De la Villa P. Depolarizing effect of GABA in rod bipolar cells of the mouse retina. Vision Res 2005;45:2659-2667.
50. Zeevalk GD, Hyndman AG, Nicklas WJ. Excitatory amino acid-induced toxicity in chick retina: amino acid release, histology, and effects of chloride channel blockers. J Neurochem 1989;53:1610-1619.
51. Krauss GL, Johnson MA, Sheth S, Miller NR. A controlled study comparing visual function in patients treated with vigabatrin and tiagabine. J Neurol Neurosurg Psychiatry 2003;74:339-343.
52. Spanaki MV, Siegel H, Kopylev L, Fazilat S, Dean A, Liow K et al. The effect of vigabatrin (gamma-vinyl GABA) on cerebral blood flow and metabolism. Neurology 1999;53:1518-1522.
53. Hosking SL, Roff Hilton EJ, Embleton SJ, Gupta AK. Epilepsy patients treated with vigabatrin exhibit reduced ocular blood flow. Br J Ophthalmol 2003;87:96-100.
54. Sorri I, Brigell MG, Malyusz M, Mahlamaki E, de Meynard C, Kalviainen R. Is reduced ornithine-delta-aminotransferase activity the cause of vigabatrin-associated visual field defects? Epilepsy Res 2010;92:48-53.
55. Daune G, Seiler N. Interrelationships between ornithine, glutamate, and GABA. II. Consequences of inhibition of GABA-T and ornithine aminotransferase in brain. Neurochem Res 1988;13:69-75.
56. Foletti GB, Delisle MC, Bachmann C. Reduction of plasma alanine aminotransferase during vigabatrin treatment. Epilepsia 1995;36:804-809.
57. Jammoul F, Degardin J, Pain D, Gondouin P, Simonutti M, Dubus E et al. Taurine deficiency damages photoreceptors and retinal ganglion cells in vigabatrin-treated neonatal rats. Mol Cell Neurosci 2010;43:414-421.
58. Jacobsen JG, Smith LH. Biochemistry and physiology of taurine and taurine derivatives. Physiol Rev 1968;48:424-511.
59. Lombardini JB. Taurine: retinal function. Brain Res Brain Res Rev 1991;16:151-169.
60. Udawatte C, Qian H, Mangini NJ, Kennedy BG, Ripps H. Taurine suppresses the spread of cell death in electrically coupled RPE cells. Mol Vis 2008;14:1940-1950.
61. Orr HT, Cohen AI, Lowry OH. The distribution of taurine in the vertebrate retina. J Neurochem 1976;26:609-611.
62. Neuringer M, Sturman JA, Wen GY, Wisniewski HM. Dietary taurine is necessary for normal retinal development in monkeys. Prog Clin Biol Res 1985;179:53-62.
63. Young TL, Cepko CL. A role for ligand-gated ion channels in rod photoreceptor development. Neuron 2004;41:867-879.
64. Massieu L, Montiel T, Robles G, Quesada O. Brain amino acids during hyponatremia in vivo: clinical observations and experimental studies. Neurochem Res 2004;29:73-81.
65. Verner A, Craig S, McGuire W. Effect of taurine supplementation on growth and development in preterm or low birth weight infants. Cochrane Database Syst Rev 2007;CD006072.
66. Hanna J, Chahine R, Aftimos G, Nader M, Mounayar A, Esseily F et al. Protective effect of taurine against free radicals damage in the rat myocardium. Exp Toxicol Pathol 2004;56:189-194.
67. Saransaari P, Oja SS. Characteristics of taurine release induced by free radicals in mouse hippocampal slices. Amino Acids 2004;26:91-98.
68. Militante JD, Lombardini JB. Taurine: evidence of physiological function in the retina. Nutr Neurosci 2002;5:75-90.
69. Leon A, Levick WR, Sarossy MG. Lesion topography and new histological features in feline taurine deficiency retinopathy. Exp Eye Res 1995;61:731-741.
70. Imaki H, Jacobson SG, Kemp CM, Knighton RW, Neuringer M, Sturman J. Retinal morphology and visual pigment levels in 6- and 12-month-old rhesus monkeys fed a taurine-free human infant formula. J Neurosci Res 1993;36:290-304.
71. Heller-Stilb B, van Roeyen C, Rascher K, Hartwig HG, Huth A, Seeliger MW et al. Disruption of the taurine transporter gene (taut) leads to retinal degeneration in mice. FASEB J 2002;16:231-233.
72. Rapp LM, Thum LA, Anderson RE. Synergism between environmental lighting and taurine depletion in causing photoreceptor cell degeneration. Exp Eye Res 1988;46:229-238.
73. Geggel HS, Ament ME, Heckenlively JR, Martin DA, Kopple JD. Nutritional requirement for taurine in patients receiving long-term parenteral nutrition. N Engl J Med 1985;312:142-146.
74. Gupta RC, Win T, Bittner S. Taurine analogues; a new class of therapeutics: retrospect and prospects. Curr Med Chem 2005;12:2021-2039.
75. Trautwein EA, Hayes KC. Taurine concentrations in plasma and whole blood in humans: estimation of error from intra- and interindividual variation and sampling technique. Am J Clin Nutr 1990;52:758-764.
76. Trautwein EA, Hayes KC. Plasma and whole blood taurine concentrations respond differently to taurine supplementation (humans) and depletion (cats). Z Ernahrungswiss 1995;34:137-142.
77. Rana SK, Sanders TA. Taurine concentrations in the diet, plasma, urine and breast milk of vegans compared with omnivores. Br J Nutr 1986;56:17-27.
78. Klein CJ. Nutrient requirements for preterm infant formulas. J Nutr 2002;132(6 Suppl 1):1395S-577S.
79. Taurine - monograph. Altern Med Rev 2001;6:78-82.
80. Shao A, Hathcock JN. Risk assessment for the amino acids taurine, l-glutamine and l-arginine. Regul Toxicol Pharmacol 2008;50:376-399.
81. Lee NY, Kang YS. The brain-to-blood efflux transport of taurine and changes in the blood-brain barrier transport system by tumor necrosis factor-alpha. Brain Res 2004;1023:141-147.
82. Sivakami S, Ganapathy V, Leibach FH, Miyamoto Y. The gamma-aminobutyric acid transporter and its interaction with taurine in the apical membrane of the bovine retinal pigment epithelium. Biochem J 1992;283(2 Pt): 391-397.
83. Tomi M, Terayama T, Isobe T, Egami F, Morito A, Kurachi M et al. Function and regulation of taurine transport at the inner blood-retinal barrier. Microvasc Res 2007;73:100-106.
84. Shimono KK, Azuma J, Ikeda T, Iwatani Y, Kimura SO et al. Temporal changes in plasma taurine level in patients with infantile spasms taking vigabatrin. Abstract 260; IEC Conference, Rome, Italy. 2011.
85. Trautwein EA, Hayes KC. Evaluating taurine status: determination of plasma and whole blood taurine concentration. J Nutr Biochem 1991;2:571-576.